

Jennifer S Graves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7917846/publications.pdf>

Version: 2024-02-01

76
papers

3,876
citations

172457

29
h-index

133252

59
g-index

77
all docs

77
docs citations

77
times ranked

4609
citing authors

#	ARTICLE	IF	CITATIONS
1	A smartphone sensor-based digital outcome assessment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 654-664.	3.0	51
2	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	5.3	39
3	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". <i>Annals of Neurology</i> , 2022, 91, 735-736.	5.3	0
4	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	12
5	Reading the "Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 177-178.	1.1	3
6	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	32
7	A systematic review and quantitative synthesis of the long-term psychiatric sequelae of pediatric autoimmune encephalitis. <i>Journal of Affective Disorders</i> , 2022, 308, 449-457.	4.1	10
8	Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110704.	3.5	0
9	Longitudinal evaluation of "neurologic" post-acute sequelae of SARS-CoV-2 infection symptoms. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 995-1010.	3.7	22
10	U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. <i>Gait and Posture</i> , 2021, 84, 120-126.	1.4	19
11	Biosensor vital sign detects multiple sclerosis progression. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 4-14.	3.7	6
12	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
13	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
14	Current Status and Future Strategies for Mentoring Women in Neurology. <i>Neurology</i> , 2021, 97, 30-37.	1.1	5
15	Encephalitis and Myelitis in a Young Woman. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1026.	6.0	1
16	CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	18
17	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	4
18	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1867-1883.	3.7	21

#	ARTICLE	IF	CITATIONS
19	What telomeres teach us about MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103084.	2.0	8
20	Quantification of smooth pursuit dysfunction in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103073.	2.0	4
21	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. <i>Cell Reports Medicine</i> , 2021, 2, 100424.	6.5	26
22	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020, 26, 894-901.	3.0	17
23	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. <i>Journal of Child Neurology</i> , 2020, 35, 77-83.	1.4	5
24	Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses. <i>JAMA Neurology</i> , 2020, 77, 327.	9.0	60
25	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1938-1947.	3.0	18
26	Dermatographism associated with ocrelizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102505.	2.0	2
27	Gut microbiota-specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , 2020, 5, .	11.9	132
28	Pediatric Multiple Sclerosis Severity Score in a large US cohort. <i>Neurology</i> , 2020, 95, e1844-e1853.	1.1	11
29	Novel MS vital sign: multi-sensor captures upper and lower limb dysfunction. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 288-295.	3.7	8
30	Biosensors to monitor MS activity. <i>Multiple Sclerosis Journal</i> , 2020, 26, 605-608.	3.0	8
31	Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 42-55.	5.3	68
32	Environmental and genetic risk factors for MS: an integrated review. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1905-1922.	3.7	165
33	Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. <i>Annals of Neurology</i> , 2019, 86, 671-682.	5.3	41
34	Vaccination. <i>Neurology</i> , 2019, 93, 377-378.	1.1	0
35	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019, 15, e1007808.	3.5	48
36	Mitochondrial Dysfunction and Multiple Sclerosis. <i>Biology</i> , 2019, 8, 37.	2.8	126

#	ARTICLE	IF	CITATIONS
37	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. <i>JAMA Network Open</i> , 2019, 2, e190570.	5.9	69
38	Silent progression in disease activity-free relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 653-666.	5.3	265
39	Optical Coherence Tomography in Multiple Sclerosis. <i>Seminars in Neurology</i> , 2019, 39, 711-717.	1.4	13
40	Puberty onset and pediatric multiple sclerosis activity in boys. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 184-187.	2.0	7
41	Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019, 34, 38-43.	1.4	7
42	Harnessing electronic medical records to advance research on multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 408-418.	3.0	21
43	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e14863.	4.3	90
44	Ovarian aging is associated with gray matter volume and disability in women with MS. <i>Neurology</i> , 2018, 90, e254-e260.	1.1	41
45	The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 161-165.	2.0	15
46	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1825-1834.	3.0	37
47	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 28-33.	1.9	74
48	Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. <i>MSystems</i> , 2018, 3, .	3.8	56
49	SVM-Based Tool to Detect Patients with Multiple Sclerosis Using a Commercial EMG Sensor. , 2018, , .		2
50	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. <i>Neurology</i> , 2018, 91, e1778-e1787.	1.1	55
51	Gender bias in American Academy of Neurology recognition awards?. <i>Neurology</i> , 2018, 91, 291-292.	1.1	7
52	Sex differences and subclinical retinal injury in pediatric-onset MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 447-455.	3.0	19
53	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017, 88, 1623-1629.	1.1	138
54	Biosensing in multiple sclerosis. <i>Expert Review of Medical Devices</i> , 2017, 14, 901-912.	2.8	20

#	ARTICLE	IF	CITATIONS
55	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , 2017, 16, 797-812.	10.2	397
56	Genetic variation in the gene <i>LRP2</i> increases relapse risk in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 864-868.	1.9	21
57	Executive Functioning in Pediatric Multiple Sclerosis: Considering the Impact of Emotional and Psychosocial Factors. <i>Journal of Pediatric Neuropsychology</i> , 2017, 3, 206-217.	0.6	0
58	Characteristics of Children and Adolescents With Multiple Sclerosis. <i>Pediatrics</i> , 2016, 138, .	2.1	89
59	Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. <i>JAMA Neurology</i> , 2016, 73, 790.	9.0	177
60	Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children. <i>Journal of Child Neurology</i> , 2016, 31, 1528-1533.	1.4	9
61	Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation—Reply. <i>JAMA Neurology</i> , 2016, 73, 1376.	9.0	4
62	Pediatric optic neuritis. <i>Neurology</i> , 2016, 87, S53-8.	1.1	47
63	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	5.3	331
64	Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents — NO. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1651-1653.	3.0	0
65	Use of Cannabinoids for Spasticity and Pain Management in MS. <i>Current Treatment Options in Neurology</i> , 2016, 18, 1.	1.8	27
66	Clinical features of neuromyelitis optica in children. <i>Neurology</i> , 2016, 86, 245-252.	1.1	100
67	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 897.	9.0	78
68	Longitudinally Extensive Optic Neuritis in Pediatric Patients. <i>Journal of Child Neurology</i> , 2015, 30, 120-123.	1.4	10
69	The US Network of Pediatric Multiple Sclerosis Centers. <i>Journal of Child Neurology</i> , 2015, 30, 1381-1387.	1.4	21
70	Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment. <i>Journal of Child Neurology</i> , 2015, 30, 1366-1370.	1.4	16
71	Rituximab Use in Pediatric Central Demyelinating Disease. <i>Pediatric Neurology</i> , 2014, 51, 114-118.	2.1	57
72	Protective environmental factors for neuromyelitis optica. <i>Neurology</i> , 2014, 83, 1923-1929.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 244-252.	2.0	32
74	Microcystic macular oedema in multiple sclerosis is associated with disease severity. <i>Brain</i> , 2012, 135, 1786-1793.	7.6	300
75	Eye disorders in patients with multiple sclerosis: natural history and management. <i>Clinical Ophthalmology</i> , 2010, 4, 1409.	1.8	51
76	Therapeutic Advances in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	28